Thus research suggests that anti-estrogen resistant breast tumors with ESR1 amplification, identified in almost 20% of metastatic ER+ breast cancers [112], as well as decreased levels of protein-folding chaperones, may be targeted by estrogen (17β-estradiol) treatment [104]. This evidence concerns the gene ESR1 and breast neoplasm.